secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K
Filed at:   2022-09-19T23:59:59+00:00
Accession:  0001628280-22-025148
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia receives EU marketing authorization for LUPKYNIS; director Walbert resigns
--------------------------------------------------------------------------------

- EC grants marketing authorization for LUPKYNIS (voclosporin) to treat active lupus nephritis in EU, Iceland, Liechtenstein, Norway, and Northern Ireland.
- Aurinia to receive $30M milestone payment from Otsuka for EC approval; cash within 30 days of invoicing.
- Director Timothy P. Walbert resigns from Board effective Sept. 19, 2022; no disagreement with company.
- LUPKYNIS previously received FDA approval in Jan. 2021 for same indication.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000162828022025148/0001628280-22-025148-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000162828022025148/auph-20220919.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-025148

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer